Investment Rating - The report assigns a "Buy" rating to WuXi XDC (02268.HK) for the first time, with a target price of HKD 80, compared to the current price of HKD 58.35 [2][11]. Core Insights - WuXi XDC is positioned to enter a commercialization phase, leveraging its end-to-end integrated CRDMO services and industry-leading technology platform to solidify its leading position in the bioconjugate drug CRDMO sector [1][15]. - The bioconjugate drug industry is experiencing rapid growth, with ADC drugs expected to reach USD 66.2 billion by 2030, and WuXi XDC projected to capture over 24% of the global ADC outsourcing market by 2025 [1][9]. Summary by Relevant Sections Company Overview - WuXi XDC is a joint venture between WuXi Biologics and Hengrui Medicine, focusing on ADC and broader bioconjugate drug markets, providing comprehensive CRDMO services [15][17]. Financial Projections - Revenue projections for WuXi XDC are as follows: - 2024: HKD 4,052 million - 2025: HKD 5,922 million (growth of 46.1%) - 2026: HKD 8,011 million (growth of 35.3%) - 2027: HKD 10,461 million (growth of 30.6%) - Net profit projections are: - 2024: HKD 1,070 million - 2025: HKD 1,481 million (growth of 38.5%) - 2026: HKD 1,989 million (growth of 34.3%) - 2027: HKD 2,600 million (growth of 30.7%) [2][11]. Industry Trends - The bioconjugate drug industry is rapidly expanding, with ADC drugs being the primary focus. The report highlights the emergence of several blockbuster ADC drugs, with six expected to exceed USD 1 billion in sales by 2025 [9][32]. - The outsourcing rate for ADC drugs is projected to remain high at approximately 60%, benefiting companies like WuXi XDC [9][29]. Technological Strengths - WuXi XDC boasts strong technical capabilities with proprietary technologies such as WuXiDARx™, X-LinC conjugation technology, and various payload conjugation platforms, enhancing its competitive edge [7][10]. Capital Expenditure and Growth Strategy - The company plans to invest HKD 1.7 billion in capital expenditures by 2026 to support its global dual-factory production strategy, enhancing its capacity for conjugated raw materials and formulations [7][10]. Market Position - WuXi XDC is expected to have a significant market share in the global ADC outsourcing market, projected to reach over 24% by 2025, reflecting its strong growth trajectory and market demand [1][9].

Investment Rating - The report initiates coverage with a "Buy" rating for WuXi XDC [1][3][4] Core Insights - The global ADC CRDMO market is expanding, with the company benefiting from a growing order pipeline and a dual-factory strategy that enhances capacity and customer retention. The company is also entering the XDC market to create a second growth curve [3][4][5] Summary by Sections Company Overview - WuXi XDC is a leading end-to-end ADC CRDMO provider, benefiting from high industry demand and a growing order book. The projected EPS for 2024-2026 is 0.89, 1.24, and 1.66 CNY respectively, with a target price of 43.4 CNY based on a 35X PE for 2025 [4][16] Market Dynamics - The global ADC drug market is expected to grow to 64.7 billion USD by 2030, with a CAGR of 30% from 2022 to 2030. The outsourcing market for ADC and broader bioconjugates is projected to reach 11 billion USD by 2030, with a CAGR of 28% [4][40] Financial Performance - The company has shown strong revenue growth, with revenues increasing from 311 million CNY in 2021 to an estimated 2.124 billion CNY in 2023, representing a CAGR of 180.7%. The net profit is expected to grow significantly, reaching 1.067 billion CNY in 2024 [8][31] Production Capacity and Strategy - The company is implementing a dual-factory strategy to enhance global production capacity, with new facilities in Singapore expected to be operational by the end of 2025. The company has 18 clinical stage III projects and is advancing its ADC pipeline [5][19][37] Growth Opportunities - The XDC market is emerging, with significant potential in non-oncological indications. The company is strategically positioned to capitalize on this growth by leveraging its existing technology and expanding its project and client base [5][21][22]